PharmaBiome AG

Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome. PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale. We are a pre-clinical stage spinoff from the ETH Zurich, combining key expertise in microbiology, biotechnology and the molecular disease mechanisms that involve the microbiome.